E-cadherin和COX-2蛋白在胃癌组织中的表达及临床意义

鲁海珍; 刘尚梅

doi:10.3969/j.issn.1000-8179.2013.08.007

E-cadherin和COX-2蛋白在胃癌组织中的表达及临床意义

doi: 10.3969/j.issn.1000-8179.2013.08.007

鲁海珍,
刘尚梅^,

中国医学科学院肿瘤医院病理科（北京市100021）

详细信息

通讯作者:
刘尚梅 liu_shangmei@sina.com

计量
- 文章访问数: 50
- HTML全文浏览量: 40
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2013-01-10
- 修回日期: 2013-02-21

Correlation of E-cadherin and COX-2 expression with clinicopathologic features of gastric adenocarcinoma

Hai zhen LU,
Shang mei LIU^,

Department of Pathology, Cancer Institute and Hospital of Chinese Academy of Medical Science, Beijing 100021, China

More Information

Corresponding author: Shangmei LIU; E-mail: liu_shangmei@sina.com

摘要

摘要: 目的研究胃癌及癌旁组织中E-钙粘附素(E-cadherin)和环氧合酶(cyclooxygenase: COX)-2的表达, 探讨蛋白表达与临床病理指标及与癌旁黏膜表达的关系。方法采用组织芯片及免疫组织化学技术, 对胃癌组织121例及118例和癌旁组织113例及111例。分别检测E-cadherin及COX-2, 并分析二者蛋白表达情况与临床病理指标相关性。结果胃癌E-cadherin阳性率为76.9%(93/121), 其表达降低与肿瘤大体分型(P=0.014)、Lauren分型(P < 0.001)、肿瘤分化(P=0.004)及pTNM分期(P=0.024)等显著相关, 分化差分期晚的肿瘤E-cadherin表达要显著低于分化好分期早的肿瘤。癌旁黏膜组织E-cadherin均呈阳性表达, 与肿瘤无显著相关。COX-2蛋白阳性率为38.1%(45/118), 其过表达与淋巴结转移相关(P=0.048), 有淋巴结转移的表达率高, 与其它病理指标无明显相关性。结论 E-cadherin及COX-2分别从肿瘤分化、分期及淋巴结转移等方面预测胃癌患者预后, 二者互补, 联合应用可做为临床预后判断的参考指标。
- 胃肿瘤 /
- E-cadherin /
- COX-2
Abstract: Objective This work aimed to evaluate the expressions of E-cadherin and cyclooxygen ase-2(COX-2) in primary gastric carcinoma and adjacent mucosa, and to investigate the correlation between abnormal expression of the said proteins and the clinico-pathological features of gastric adenocarcinoma. Methods Immunohistochemical staining was used to determine the expression of E-cadherin and COX-2 on tissue microarray slices obtained from gastric carcinoma and adjacent mucosa of over 100 cases from the Cancer Institute and Hospital of Chinese Academy of Medical Science between February 2005 and October 2006. Results The positive expressions of E-cadherin and COX-2 were 76.9%(93/121) and 38.1%(45/118), respectively, in gastric carcinoma, whereas E-cadherin expression was 100% in 113 cases with adjacent mucosa.The positive expression of E-cadherin was significantly correlated with clinical characteristics such as gross type(P=0.014), differentiation(P=0.004), and pTNM stage(P=0.024).COX-2 expression was higher in gastric cancer cases with lymph node me tastasis than those without, and the result was significantly different(P=0.048). Conclusion E-cadherin is a tumor-inhibiting factor and COX-2 is a carcinogen.Positive expression of E-cadherin and negative expression of COX-2 are correlated with better prognosis.E-cadherin and COX-2 may thus be used as potential markers of tumor progression and prognosis.
- gastric tumor /
- E-cadherin /
- COX-2

HTML全文

图 1 E-cadherin蛋白免疫组化强阳性表达(S-P法×100)

Figure 1. E-cadherin expression determined by immunohistochemistry(SP method×100)

下载: 全尺寸图片幻灯片

图 2 COX-2蛋白免疫组化阳性表达(S-P法×100)

Figure 2. COX-2 expression determined by immunohistochemistry(SP method×100)

下载: 全尺寸图片幻灯片

表 1 E-cadherin蛋白表达与临床病理参数相关性（例%）

Table 1. Association of E-cadherin protein expression with clinicopathologic characteristics

表 2 COX-2蛋白表达与淋巴结转移相关性（例%）

Table 2. Association of COX-2 protein expression with lymph node metastasis

参考文献(14)

[1]	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108. doi: 10.3322/canjclin.55.2.74
[2]	Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellulardynamics and in cancer[J]. J Cell Physiol, 2002, 190(3): 279-286. doi: 10.1002/jcp.10068
[3]	Graziano F, Arduini F, Ruzzo A, et al. Prognostic analysis of E-cad herin gene promoter hypermethylation in patients with surgically re sected, nodepositive, diffuse gastric cancer[J]. Clin Cancer Res, 2004, 10(8): 2784-2789. doi: 10.1158/1078-0432.CCR-03-0320
[4]	Uchikado Y, Okumura H, Ishigami S, et al. Increased Slug and de creased E-cadherin expression is related to poor prognosis in pa tients with gastric cancer[J]. Gastric Cancer, 2011, 14(1): 41-49. doi: 10.1007/s10120-011-0004-x
[5]	Xing X, Tang YB, Yuan G, et al. The prognostic value of E-cad herin in gastric cancer: A meta-analysis[J]. Int J Cancer, 2012, Pub lished online.
[6]	Zhou Y, Li G, Wu J, et al. Clinicopathological significance ofE-cadherin, VEGF, and MMPs in gastric cancer[J]. Tumour Biol, 2010, 31(6): 549-558. doi: 10.1007/s13277-010-0068-y
[7]	Tang B, Peng ZH, Yu PW, et al. Expression and significance ofCx43 and E-cadherin in gastric cancer and metastatic lymph nodes[J]. Med Oncol, 2011, 28(2): 502-508. doi: 10.1007/s12032-010-9492-5
[8]	Chan AO, Chu KM, Lam SK, et al. Soluble E-cadherin is an inde pendent pretherapeutic factor for long-term survival in gastric can cer[J]. J Clin Oncol, 2003, 21(12): 2288-2293. doi: 10.1200/JCO.2003.08.078
[9]	姬社青, 花亚伟, 庄兢, 等. COX-2、p53、PCNA和nm23异常表达与胃癌生物学行为的关系[J]. 癌症, 2002, 21(6): 619-624. https://www.cnki.com.cn/Article/CJFDTOTAL-AIZH200206010.htm
[10]	Uefuji K, Ichikura T, Mochizuki H. CycIooxygenase-2 expressionis related to prostaglandin biosynthesis and angiogenesis in humangastric cancer[J]. CIin Cancer Res, 2000, 6(1): 135-138.
[11]	Gou HF, Chen XC, Zhu J, et al. Expressions of COX-2 andVEGF-C in gastric cancer: correlations with lymphangiogenesisand prognostic implications[J]. J Exp Clin Cancer Res, 2011, 30: 14. doi: 10.1186/1756-9966-30-14
[12]	Han SL, Tang HJ, Hua YW, et al. Expression of COX-2 in stom ach cancers and its relation to their biological features[J]. Dig Surg, 2003, 20(2): 107-114. doi: 10.1159/000069384
[13]	Fujita T, Matsui M, Takaku K, et al. Size-and invasiondependentincrease in cyclooxygenase 2 levels in human colorectal carcinomas[J]. Cancer Res, 1998, 58(21): 4823-4826.
[14]	Mrena J, Wiksten JP, Kokkola A, et al. COX-2 is associated withproliferation and apoptosis markers and serves as an independentprognostic factor in gastric cancer[J]. Tumour Biol, 2010, 31(1): 1-7. doi: 10.1007/s13277-009-0001-4